ArticleBMC urology2026
Prostate-specific antigen clearance after surgery for benign prostate enlargement in a cohort with median prostate-specific antigen greater than 4ng/ml.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotal prostate-specific antigen (tPSA) could be elevated in some cases of benign prostate enlargement (BPE). The aim of this study is to evaluate tPSA clearance after surgery for BPE with histologic confirmation of nodular hyperplasia.
methodsMen for transurethral resection of the prostate (TURP), or open simple prostatectomy (OSP), with benign imaging features of the prostate were recruited. Those with tPSA >4ng/ml, but benign core-needle biopsy reports were recruited as well. A control arm of men on Tamsulosin+Dutasteride therapy (TDT) for BPE was also recruited. Participants with histologic finding of chronic prostatitis or malignancy at biopsy or post extirpation were excluded. Age, body mass index (BMI), prostate volume (PV) and presenting clinical features were noted. The tPSA values were taken at baseline, 6 weeks and 12 weeks post intervention. The mass of resected or enucleated prostate tissue was noted and the tPSA clearance curve was plotted.
resultsThere were 154 participants: 77 were on TDT, 43 had monopolar TURP and 34 had OSP. The TDT patients were younger (61.57 ± 6.93years TDT vs. 65.4 ± 9.08years TURP vs. 63.71 ± 7.23years OSP; p 0.03), had lower median tPSA [5.6(4.0–7.6)ng/ml TDT vs. 10.0(5.7–13.1)ng/ml TURP vs. 15.8(9.0–20.0)ng/ml OSP; p < 0.001], and had lower PV (51.96 ± 5.22 ml TDT vs. 62.42 ± 7.16 ml TURP vs. 113.13 ± 29.57 ml OSP; p < 0.001) at recruitment. The 3 groups had similar BMI (26.25 ± 1.68 kg/m2 TDT vs. 25.72 ± 2.72 kg/m2 TURP vs. 26.05 ± 2.23 kg/m2 OSP; p 0.44). The tPSA clearance post-surgery correlated with the pre-surgery tPSA and was at a rate of y = 11.168e− 0.151x (y=tPSA; x=time). At 6 weeks post-surgery, 45.5% had tPSA < 4.0ng/ml, and at 12 weeks, 96.1% had tPSA < 4.0ng/ml.
conclusionWhere tPSA is ≥ 1.5ng/ml in BPE, surgery in form of TURP or OSP results in exponential decrease in serum tPSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.